AVTX Stock — Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. (AVTX)

Updated October 16, 2026.

AVTX is a Stock. Its deepest 1-year drawdown was 50.7%.

Avalo Therapeutics is a clinical-stage biotechnology company developing IL-1ß-based treatments for immune-mediated inflammatory diseases, with its lead candidate AVTX-009, a humanized monoclonal antibody, currently in phase 2 clinical trials. The company does not currently pay distributions. As an early-stage biotech firm with no approved products generating revenue, it is oriented toward investors seeking exposure to clinical development risk and potential long-term capital appreciation rather than income.

AVTX performance

Returns are updating. AVTX's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 50.7%.

AVTX key facts

Asset type

Stock

Asset class

Equity

Inception date

10/14/2015

Distribution frequency

None

Last close

$11.27 (as of 2026-10-16)

Market cap

$604,409,976

Average volume

971072.0

Beta

0.695

Payout ratio

0.0%

EPS

$-4.31

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

AVTX risks and drawbacks

The deepest 1-year drawdown on record here is 50.7%.

Who may consider AVTX — and who may not

It is a weaker fit for investors who need monthly cash flow (AVTX does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on AVTX

• All tickers starting with A

Tagged: Healthcare.

Frequently asked questions